EBRO 2017

Larynx preservation: larynx carcinoma

Distribution by T-stage:

5-yr-overall survival:

Radiotherapy with concurrent cisplatin 54% Radiotherapy with neoadjuvant chemotherapy 58% Conventional radiotherapy alone 55%

Forastiere et al. NEJM, 2003; JCO, 2013